Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPGx-001 in LCA5-Associated Inherited Retinal Degeneration
NCT05616793Phase 2Recruiting
- Sponsor
- Opus Genetics
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of OPGx-001 in Leber congenital amaurosis type 5 (LCA5), sponsored by Opus Genetics. Started Jun 2023; status: recruiting.
02
Drugs
OPGx-001
03
Conditions
Leber congenital amaurosis type 5 (LCA5)
Beyond the preview
Go deeper on NCT05616793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616793.